Semaglutide vs Liraglutide
Side-by-Side Comparison
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Metabolic / GLP-1 Agonist |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. | Liraglutide binds to GLP-1 receptors on pancreatic β-cells, increasing intracellular cAMP and triggering glucose-dependent insulin secretion. |
| Evidence Rating | A — FDA Approved | A — FDA Approved |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | FDA-approved (Victoza for T2D, Saxenda for obesity) |
| Safety Profile | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness | Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%); GI side effects are dose-dependent and typically diminish over weeks |
| Route | Subcutaneous (weekly injection); Oral tablet available (Rybelsus) | Subcutaneous |
| Dose Range | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day | Saxenda: 0.6-3.0 mg/day; Victoza: 0.6-1.8 mg/day |
| Frequency | Once weekly (SC); Once daily (oral) | Once daily |
| Molecular Weight | ~4113.6 g/mol | ~3,751 g/mol |
| Half-Life | ~160–168 hours (~7 days) | ~13 hours |
Overview
Semaglutide and Liraglutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Semaglutide — Mechanism & Evidence
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). Developed by Novo Nordisk and first FDA-approved December 5, 2017, it is backed by the extensive STEP and SUSTAIN trial programs involving thousands of patients. There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
Liraglutide — Mechanism & Evidence
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was the first GLP-1 agonist approved for obesity. While effective, it has been largely superseded by semaglutide (once-weekly dosing, greater weight loss) — liraglutide requires daily injection and achieves approximately 8% weight loss vs semaglutide's 15%.
Key claims: Clinically significant weight loss; Improves glycemic control; Cardiovascular benefit.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health, Cardiovascular.
Semaglutide is also researched for: no additional unique applications.
Liraglutide is also researched for: no additional unique applications.
Safety Considerations
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Liraglutide: Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%) GI side effects are dose-dependent and typically diminish over weeks FDA black box warning for thyroid C-cell tumors (rodent data)
Related Products
Semaglutide 10mg
10mg
Related Research News
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.